Mike, when the same question gets asked five different ways by five different posters, sometimes under different names, sometimes with identical tone, it becomes obvious that something deeper is happening. It is not genuine curiosity. It is a strategy. The goal is not to uncover truth. It is to fragment it. One poster isolates a sentence from one thread, strips it of context, and pretends the entire argument rests on that one remark. Another asks a parallel version of the same question in a new thread. This is not dialogue. This is disruption by repetition.
This pattern aims to prevent coherence. The tactic is to ensure no single version of the full answer ever appears in one place. If a reader catches one explanation but not the others, the next claim becomes, “See, it wasn’t addressed.” The trick only works if no one bothers to unify the facts. So that’s exactly what this post is going to do. It will consolidate every step of the process, documented, ordered, and tied directly to the regulatory record.
The Timeline Begins: Submission and Validation
Let us start at the beginning. Northwest Biotherapeutics submitted its Marketing Authorisation Application (MAA) to the UK Medicines and Healthcare products Regulatory Agency (MHRA) on December 20, 2023. This is the official application to have DCVax-L approved for use. The MHRA’s first task is validation, checking that the file is complete, with the correct structure, data formats, and module inclusion. This is administrative housekeeping, not scientific review.
Once validated, the real review begins. It covers multiple dimensions: clinical efficacy, manufacturing consistency (CMC), and pharmacovigilance plans. For personalized therapies like DCVax-L, the manufacturing section becomes crucial. Regulators must confirm that patient-specific doses can be safely and reproducibly manufactured every time.
RFIs Are Normal, But the Clock Keeps Ticking
During the review, the MHRA can issue Requests for Information (RFIs). These are standard. They do not signal a problem. They are the mechanism regulators use to clarify points, request additional data, or confirm process integrity. Some RFIs are resolved in days, others in weeks. We do not know if or when RFIs were issued in this case. But we do know that the company continued forward.
What matters is not whether there were questions in February or April. What matters is what NICE confirmed on July 15: that Northwest Biotherapeutics remains fully engaged in the MAA process and is not yet in a position to submit to NICE. That language is not neutral. It is regulatory code, and it tells us the process is in its final phase.
Silence Is Not Delay. Silence Is Law
The mistake people often make is assuming that silence equals a problem. In regulatory frameworks, particularly in the UK, silence during this stage is expected. Once an internal approval is granted, both the agency and the sponsor are restricted from public comment while final documentation is being finalized.
If the process had stalled, NICE would not describe the company as fully engaged. If the MAA had been rejected or paused, NICE would not be waiting. The agency’s statement is precise. It says that the company is preparing to submit but lacks one key piece. That piece is the final regulatory label, known as the Summary of Product Characteristics (SmPC).
PMG24 and the Legal Requirement of the SmPC
The SmPC is not optional. Under NICE’s official submission manual, PMG24, a company cannot submit its evidence for pricing and reimbursement unless it possesses the finalized SmPC. This document defines the product’s identity. It lists the patient population, administration method, usage conditions, and risks. NICE uses the SmPC as the legal definition of what has been approved, and without it, no modeling of benefit or cost can begin.
This is not a vague requirement. It is black and white. PMG24 mandates that NICE will not initiate the appraisal process until the regulator-approved SmPC is in hand. So when NICE says Northwest Biotherapeutics is not yet in a position to submit, it is almost certainly referring to the fact that the SmPC is not yet finalized.
Labeling Is the Final Step Before Approval Becomes Public
The SmPC is only written after the internal approval decision has been made. It is a joint effort between the MHRA and the company. It typically takes two to four weeks to finalize. During this time, silence is legally enforced. The sponsor cannot issue a press release, and the regulator cannot pre-announce its decision. That is why the system appears quiet. It is not confusion. It is deliberate structure.
Once the SmPC is complete, it triggers everything else: the public announcement, the NICE submission, and the broader access pathway. But until that document is finished, everything else waits.
What the July 15 Letter Actually Reveals
Let us look again at the language in the July 15 letter from NICE. It states that Northwest Biotherapeutics is still fully engaged with the MHRA and not yet in a position to submit to NICE. That is not commentary. It is procedural disclosure. NICE cannot begin without a finalized label. And the only way the company could be fully engaged in the MAA process and yet not able to submit is if the review has concluded and the SmPC is the only piece outstanding.
This is not speculation. It is exactly what PMG24 describes. It means the MHRA has completed its internal scientific review and is now working with the company to finalize the wording of the approval documents. That process is called labeling. It is the end, not the middle.
The Regulatory Sequence Cannot Be Skipped
The SmPC cannot be finalized before internal approval. NICE cannot accept a submission without that label. And the company cannot speak publicly during this stage. Each step depends on the one before it. This sequence is not interpretive. It is procedural law. That is why the silence exists, and it is why the July 15 letter was issued exactly when it was.
If someone argues that the company is still undergoing review, or that RFIs are ongoing, they are ignoring the policy chain. RFIs stop the clock. Final labeling does not occur until the RFIs are resolved and the review has concluded. NICE cannot be on standby unless the end is near.
Timing Is Still On Track
The application was submitted on December 20, 2023. Assuming a typical validation and review start in January, the process has now run just over seven months. This is in line with historical timelines for Advanced Therapy Medicinal Products. Even if we assume minor delays for RFIs, we are still inside the expected window.
The labeling phase itself usually lasts two to four weeks. Several precedents support this: BioMarin’s Roctavian, Janssen’s Carvykti, and Orchard’s Libmeldy each had finalization windows in the same range. That is the stage we are in now, where internal approval has been granted, and public disclosure is pending final document formatting.
The System Is Not Broken. It Is Executing.
If the MHRA finalized its internal decision in late June or early July, and began labeling immediately, we are now three to five weeks into the silent zone. This aligns perfectly with precedent. The July 15 NICE letter fits that timing. The language in the letter is exact. The structure of PMG24 is binding. The combination of these two signals tells us the same thing: approval has occurred internally, and the public handoff is imminent.
Nothing in this sequence is out of place. Every known fact, every procedural step, and every timing benchmark lines up. There is no mystery. There is no contradiction. There is only a quiet moment between the regulator’s decision and the sponsor’s announcement. That is where we are. That is what the system was built to do.
The Burden of Rebuttal Is Now on the Deniers
So, Mike, if you want to argue this is speculation, you need to offer more than opinion. You need to explain why NICE is waiting. You need to explain how the company could be fully engaged with MHRA if the file were paused or deficient. You need to explain how submission is blocked without an SmPC, yet the company is still active in the process. And you need to do so without disregarding PMG24 or misrepresenting what the July 15 letter actually says.
Because until you do, the structure of the process speaks louder than any post, tweet, or guess. The review is over. The label is being finalized. And the silence you keep pointing to is not evidence of failure. It is the sound of an approval system doing exactly what it was designed to do.
Finalization, not speculation, is the story now. And there is nothing left to misinterpret.
To the iHub Moderators:
Given the repetitive nature of the questions, the ongoing attempts to fragment the discussion, and the need for a single, complete reference point, I respectfully ask the iHub admins to pin this post. It consolidates the entire procedural timeline using public documents and verifiable regulatory policy. Pinning this will prevent redundancy, reduce confusion, and allow any future debate to begin from a position of shared understanding. Thank you.
Market Data 
Markets 
AI
